Risk of Strongyloides Hyperinfection Syndrome when prescribing Dexamethasone in Severe COVID-19
Risk of Strongyloides Hyperinfection Syndrome when prescribing Dexamethasone in Severe COVID-19
About this item
Full title
Author / Creator
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Strongyloides stercoralis, a parasitic nematode infection endemic in tropical and subtropical regions, is estimated to infect 30 to 100 million people worldwide. Patients deemed at high risk (migrants with high risk exposure) may need empirical treatment with ivermectin, which has an efficacy of 85% as a single dose [5]. COVID-19 patients with undi...
Alternative Titles
Full title
Risk of Strongyloides Hyperinfection Syndrome when prescribing Dexamethasone in Severe COVID-19
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7847532
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7847532
Other Identifiers
ISSN
1477-8939
E-ISSN
1873-0442
DOI
10.1016/j.tmaid.2021.101981
